REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead-in phase while receiving standard-of-care therapy off study. Approximately 4 weeks after temozolomide, participants will receive one study-specific 2 Gy fraction of maintenance radiotherapy directed at the post-operative cavity and areas of prior enhancing disease. The study will evaluate the safe

Trial Details

NCT ID
NCT07831772
Phase
NA
Sponsor
University of Minnesota
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Maintenance Radiotherapy
Locations (sample)
  • Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

  • Histologically confirmed diagnosis of glioblastoma according to WHO classification criteria for which standard-of-care surgical resection, concurre…
  • Planning to receive standard-of-care radiotherapy with a biological effective dose of 60 Gy or less in 30 fractions
  • Age 18 years or older at the time of consent
  • Karnofsky performance status of 70 or higher

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →